IO Biotech Net Worth
IO Biotech Net Worth Breakdown | IOBT |
IO Biotech Net Worth Analysis
IO Biotech's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including IO Biotech's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of IO Biotech's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform IO Biotech's net worth analysis. One common approach is to calculate IO Biotech's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares IO Biotech's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing IO Biotech's net worth. This approach calculates the present value of IO Biotech's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of IO Biotech's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate IO Biotech's net worth. This involves comparing IO Biotech's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into IO Biotech's net worth relative to its peers.
Enterprise Value |
|
To determine if IO Biotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding IO Biotech's net worth research are outlined below:
| IO Biotech has some characteristics of a very speculative penny stock | |
| IO Biotech had very high historical volatility over the last 90 days | |
| Net Loss for the year was (86.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| IO Biotech currently holds about 170.12 M in cash with (71.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| IO Biotech has a frail financial position based on the latest SEC disclosures | |
| Roughly 67.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: IO Biotech Upgraded to Strong-Buy at Piper Sandler |
IO Biotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in IO Biotech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to IO Biotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know IO Biotech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as IO Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading IO Biotech backward and forwards among themselves. IO Biotech's institutional investor refers to the entity that pools money to purchase IO Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bridgeway Capital Management, Llc | 2024-12-31 | 174 K | Renaissance Technologies Corp | 2024-12-31 | 118.8 K | Sectoral Asset Management Inc | 2024-12-31 | 75 K | Royal Bank Of Canada | 2024-12-31 | 60 K | Ubs Group Ag | 2024-12-31 | 47 K | Geode Capital Management, Llc | 2024-12-31 | 33.3 K | Vontobel Holding Ltd. | 2024-12-31 | 32.7 K | Xtx Topco Ltd | 2024-12-31 | 28 K | Pks Advisory Services, Llc | 2024-12-31 | 16 K | Vivo Capital, Llc | 2024-12-31 | 6.2 M | Novo A/s | 2024-12-31 | 3.4 M |
Follow IO Biotech's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 57.9 M.Market Cap |
|
Project IO Biotech's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.51) | (0.54) | |
| Return On Capital Employed | (0.78) | (0.74) | |
| Return On Assets | (0.51) | (0.54) | |
| Return On Equity | (0.74) | (0.71) |
When accessing IO Biotech's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures IO Biotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of IO Biotech's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in IO Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of IO Biotech. Check IO Biotech's Beneish M Score to see the likelihood of IO Biotech's management manipulating its earnings.
Evaluate IO Biotech's management efficiency
IO Biotech has return on total asset (ROA) of (0.4591) % which means that it has lost $0.4591 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.785) %, meaning that it created substantial loss on money invested by shareholders. IO Biotech's management efficiency ratios could be used to measure how well IO Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.54 in 2025. Return On Capital Employed is likely to gain to -0.74 in 2025. Non Current Liabilities Other is likely to gain to about 2.7 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 11.1 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.75 | 2.11 | |
| Tangible Book Value Per Share | 2.75 | 2.11 | |
| Enterprise Value Over EBITDA | 0.58 | 0.61 | |
| Price Book Value Ratio | 0.55 | 0.58 | |
| Enterprise Value Multiple | 0.58 | 0.61 | |
| Price Fair Value | 0.55 | 0.58 | |
| Enterprise Value | -84.6 M | -80.3 M |
IO Biotech's management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific IO Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on IO Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases IO Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
IO Biotech time-series forecasting models is one of many IO Biotech's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary IO Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
IO Biotech Earnings per Share Projection vs Actual
IO Biotech Corporate Management
| MaiBritt Zocca | President, Founder | Profile | |
| Qasim MD | Chief Officer | Profile | |
| Faical Miyara | Chief Officer | Profile | |
| Brian CPA | Chief Officer | Profile | |
| Amy Sullivan | Chief Officer | Profile | |
| Anders Ljungqvist | Founder | Profile | |
| Brian Burkavage | Chief Officer | Profile |
Additional Tools for IOBT Stock Analysis
When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.